Hancock Jaffe Laboratories (NASDAQ: HJLI) Stock Competitors & Peer Comparison

Hancock Jaffe Laboratories (NASDAQ: HJLI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HJLI stands at 98.3M. In comparison, BSX-PA has a market cap of 175.4B. Regarding current trading prices, HJLI is priced at $10.38 on the NASDAQ, while BSX-PA trades at $122.18.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HJLI currently has a P/E ratio of N/A, whereas BSX-PA's P/E ratio is 230.53. In terms of profitability, HJLI's ROE is -0.62%, compared to BSX-PA's ROE of +0.15%. Regarding short-term risk, HJLI is more volatile compared to BSX-PA. This indicates higher risk in terms of short-term price fluctuations for HJLI.Check BSX-PA's competition here

Hancock Jaffe Laboratories (NASDAQ: HJLI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HJLI stands at 98.3M. In comparison, ABT has a market cap of 174.7B. Regarding current trading prices, HJLI is priced at $10.38 on the NASDAQ, while ABT trades at $100.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HJLI currently has a P/E ratio of N/A, whereas ABT's P/E ratio is 19.37. In terms of profitability, HJLI's ROE is -0.62%, compared to ABT's ROE of +0.11%. Regarding short-term risk, HJLI is more volatile compared to ABT. This indicates higher risk in terms of short-term price fluctuations for HJLI.Check ABT's competition here

Hancock Jaffe Laboratories (NASDAQ: HJLI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HJLI stands at 98.3M. In comparison, MDT has a market cap of 111.5B. Regarding current trading prices, HJLI is priced at $10.38 on the NASDAQ, while MDT trades at $87.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HJLI currently has a P/E ratio of N/A, whereas MDT's P/E ratio is 15.75. In terms of profitability, HJLI's ROE is -0.62%, compared to MDT's ROE of +0.11%. Regarding short-term risk, HJLI is more volatile compared to MDT. This indicates higher risk in terms of short-term price fluctuations for HJLI.Check MDT's competition here

Hancock Jaffe Laboratories (NASDAQ: HJLI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HJLI stands at 98.3M. In comparison, SYK has a market cap of 106.9B. Regarding current trading prices, HJLI is priced at $10.38 on the NASDAQ, while SYK trades at $278.77.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HJLI currently has a P/E ratio of N/A, whereas SYK's P/E ratio is 20.83. In terms of profitability, HJLI's ROE is -0.62%, compared to SYK's ROE of +0.16%. Regarding short-term risk, HJLI is more volatile compared to SYK. This indicates higher risk in terms of short-term price fluctuations for HJLI.Check SYK's competition here

Hancock Jaffe Laboratories (NASDAQ: HJLI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HJLI stands at 98.3M. In comparison, BSX has a market cap of 65.2B. Regarding current trading prices, HJLI is priced at $10.38 on the NASDAQ, while BSX trades at $43.88.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HJLI currently has a P/E ratio of N/A, whereas BSX's P/E ratio is 14.15. In terms of profitability, HJLI's ROE is -0.62%, compared to BSX's ROE of +0.15%. Regarding short-term risk, HJLI is more volatile compared to BSX. This indicates higher risk in terms of short-term price fluctuations for HJLI.Check BSX's competition here

Hancock Jaffe Laboratories (NASDAQ: HJLI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HJLI stands at 98.3M. In comparison, EW has a market cap of 50.7B. Regarding current trading prices, HJLI is priced at $10.38 on the NASDAQ, while EW trades at $88.08.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HJLI currently has a P/E ratio of N/A, whereas EW's P/E ratio is 32.63. In terms of profitability, HJLI's ROE is -0.62%, compared to EW's ROE of +0.10%. Regarding short-term risk, HJLI is more volatile compared to EW. This indicates higher risk in terms of short-term price fluctuations for HJLI.Check EW's competition here

Hancock Jaffe Laboratories (NASDAQ: HJLI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HJLI stands at 98.3M. In comparison, DXCM has a market cap of 32.7B. Regarding current trading prices, HJLI is priced at $10.38 on the NASDAQ, while DXCM trades at $86.64.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HJLI currently has a P/E ratio of N/A, whereas DXCM's P/E ratio is 33.98. In terms of profitability, HJLI's ROE is -0.62%, compared to DXCM's ROE of +0.36%. Regarding short-term risk, HJLI is more volatile compared to DXCM. This indicates higher risk in terms of short-term price fluctuations for HJLI.Check DXCM's competition here

Hancock Jaffe Laboratories (NASDAQ: HJLI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HJLI stands at 98.3M. In comparison, GEHC has a market cap of 30B. Regarding current trading prices, HJLI is priced at $10.38 on the NASDAQ, while GEHC trades at $66.46.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HJLI currently has a P/E ratio of N/A, whereas GEHC's P/E ratio is 14.57. In terms of profitability, HJLI's ROE is -0.62%, compared to GEHC's ROE of +0.15%. Regarding short-term risk, HJLI is more volatile compared to GEHC. This indicates higher risk in terms of short-term price fluctuations for HJLI.Check GEHC's competition here

Hancock Jaffe Laboratories (NASDAQ: HJLI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HJLI stands at 98.3M. In comparison, PHG has a market cap of 24.2B. Regarding current trading prices, HJLI is priced at $10.38 on the NASDAQ, while PHG trades at $24.77.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HJLI currently has a P/E ratio of N/A, whereas PHG's P/E ratio is 14.15. In terms of profitability, HJLI's ROE is -0.62%, compared to PHG's ROE of +0.10%. Regarding short-term risk, HJLI is more volatile compared to PHG. This indicates higher risk in terms of short-term price fluctuations for HJLI.Check PHG's competition here

Hancock Jaffe Laboratories (NASDAQ: HJLI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HJLI stands at 98.3M. In comparison, ZBH has a market cap of 17.7B. Regarding current trading prices, HJLI is priced at $10.38 on the NASDAQ, while ZBH trades at $91.34.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HJLI currently has a P/E ratio of N/A, whereas ZBH's P/E ratio is 10.77. In terms of profitability, HJLI's ROE is -0.62%, compared to ZBH's ROE of +0.06%. Regarding short-term risk, HJLI is more volatile compared to ZBH. This indicates higher risk in terms of short-term price fluctuations for HJLI.Check ZBH's competition here

Hancock Jaffe Laboratories (NASDAQ: HJLI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HJLI stands at 98.3M. In comparison, ABMD has a market cap of 17.2B. Regarding current trading prices, HJLI is priced at $10.38 on the NASDAQ, while ABMD trades at $381.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HJLI currently has a P/E ratio of N/A, whereas ABMD's P/E ratio is 65.36. In terms of profitability, HJLI's ROE is -0.62%, compared to ABMD's ROE of +0.10%. Regarding short-term risk, HJLI is more volatile compared to ABMD. This indicates higher risk in terms of short-term price fluctuations for HJLI.Check ABMD's competition here

Hancock Jaffe Laboratories (NASDAQ: HJLI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HJLI stands at 98.3M. In comparison, SWAV has a market cap of 12.6B. Regarding current trading prices, HJLI is priced at $10.38 on the NASDAQ, while SWAV trades at $334.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HJLI currently has a P/E ratio of N/A, whereas SWAV's P/E ratio is 78.76. In terms of profitability, HJLI's ROE is -0.62%, compared to SWAV's ROE of +0.25%. Regarding short-term risk, HJLI is more volatile compared to SWAV. This indicates higher risk in terms of short-term price fluctuations for HJLI.Check SWAV's competition here

Hancock Jaffe Laboratories (NASDAQ: HJLI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HJLI stands at 98.3M. In comparison, PEN has a market cap of 12.6B. Regarding current trading prices, HJLI is priced at $10.38 on the NASDAQ, while PEN trades at $318.86.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HJLI currently has a P/E ratio of N/A, whereas PEN's P/E ratio is 83.26. In terms of profitability, HJLI's ROE is -0.62%, compared to PEN's ROE of +0.11%. Regarding short-term risk, HJLI is more volatile compared to PEN. This indicates higher risk in terms of short-term price fluctuations for HJLI.Check PEN's competition here

Hancock Jaffe Laboratories (NASDAQ: HJLI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HJLI stands at 98.3M. In comparison, SNN has a market cap of 11.3B. Regarding current trading prices, HJLI is priced at $10.38 on the NASDAQ, while SNN trades at $26.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HJLI currently has a P/E ratio of N/A, whereas SNN's P/E ratio is 18.19. In terms of profitability, HJLI's ROE is -0.62%, compared to SNN's ROE of +0.12%. Regarding short-term risk, HJLI is more volatile compared to SNN. This indicates higher risk in terms of short-term price fluctuations for HJLI.Check SNN's competition here

Hancock Jaffe Laboratories (NASDAQ: HJLI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HJLI stands at 98.3M. In comparison, BIO-B has a market cap of 10.5B. Regarding current trading prices, HJLI is priced at $10.38 on the NASDAQ, while BIO-B trades at $385.54.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HJLI currently has a P/E ratio of N/A, whereas BIO-B's P/E ratio is -67.89. In terms of profitability, HJLI's ROE is -0.62%, compared to BIO-B's ROE of +0.03%. Regarding short-term risk, HJLI is more volatile compared to BIO-B. This indicates higher risk in terms of short-term price fluctuations for HJLI.Check BIO-B's competition here

Hancock Jaffe Laboratories (NASDAQ: HJLI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HJLI stands at 98.3M. In comparison, ALGN has a market cap of 10.3B. Regarding current trading prices, HJLI is priced at $10.38 on the NASDAQ, while ALGN trades at $144.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HJLI currently has a P/E ratio of N/A, whereas ALGN's P/E ratio is 13.13. In terms of profitability, HJLI's ROE is -0.62%, compared to ALGN's ROE of +0.10%. Regarding short-term risk, HJLI is more volatile compared to ALGN. This indicates higher risk in terms of short-term price fluctuations for HJLI.Check ALGN's competition here

Hancock Jaffe Laboratories (NASDAQ: HJLI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HJLI stands at 98.3M. In comparison, BIO has a market cap of 10.2B. Regarding current trading prices, HJLI is priced at $10.38 on the NASDAQ, while BIO trades at $379.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HJLI currently has a P/E ratio of N/A, whereas BIO's P/E ratio is 40.90. In terms of profitability, HJLI's ROE is -0.62%, compared to BIO's ROE of +0.03%. Regarding short-term risk, HJLI is more volatile compared to BIO. This indicates higher risk in terms of short-term price fluctuations for HJLI.Check BIO's competition here

Hancock Jaffe Laboratories (NASDAQ: HJLI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HJLI stands at 98.3M. In comparison, GMED has a market cap of 10.2B. Regarding current trading prices, HJLI is priced at $10.38 on the NASDAQ, while GMED trades at $75.69.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HJLI currently has a P/E ratio of N/A, whereas GMED's P/E ratio is 17.06. In terms of profitability, HJLI's ROE is -0.62%, compared to GMED's ROE of +0.12%. Regarding short-term risk, HJLI is more volatile compared to GMED. This indicates higher risk in terms of short-term price fluctuations for HJLI.Check GMED's competition here

Hancock Jaffe Laboratories (NASDAQ: HJLI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HJLI stands at 98.3M. In comparison, BRKR has a market cap of 9.8B. Regarding current trading prices, HJLI is priced at $10.38 on the NASDAQ, while BRKR trades at $64.51.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HJLI currently has a P/E ratio of N/A, whereas BRKR's P/E ratio is 32.42. In terms of profitability, HJLI's ROE is -0.62%, compared to BRKR's ROE of -0.03%. Regarding short-term risk, HJLI is more volatile compared to BRKR. This indicates higher risk in terms of short-term price fluctuations for HJLI.Check BRKR's competition here

Hancock Jaffe Laboratories (NASDAQ: HJLI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HJLI stands at 98.3M. In comparison, BRKRP has a market cap of 9.5B. Regarding current trading prices, HJLI is priced at $10.38 on the NASDAQ, while BRKRP trades at $470.78.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HJLI currently has a P/E ratio of N/A, whereas BRKRP's P/E ratio is 256.72. In terms of profitability, HJLI's ROE is -0.62%, compared to BRKRP's ROE of -0.03%. Regarding short-term risk, HJLI is more volatile compared to BRKRP. This indicates higher risk in terms of short-term price fluctuations for HJLI.Check BRKRP's competition here

Hancock Jaffe Laboratories (NASDAQ: HJLI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HJLI stands at 98.3M. In comparison, MASI has a market cap of 9.4B. Regarding current trading prices, HJLI is priced at $10.38 on the NASDAQ, while MASI trades at $179.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HJLI currently has a P/E ratio of N/A, whereas MASI's P/E ratio is 44.43. In terms of profitability, HJLI's ROE is -0.62%, compared to MASI's ROE of +0.09%. Regarding short-term risk, HJLI is more volatile compared to MASI. This indicates higher risk in terms of short-term price fluctuations for HJLI.Check MASI's competition here

Hancock Jaffe Laboratories (NASDAQ: HJLI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HJLI stands at 98.3M. In comparison, GKOS has a market cap of 9.4B. Regarding current trading prices, HJLI is priced at $10.38 on the NASDAQ, while GKOS trades at $158.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HJLI currently has a P/E ratio of N/A, whereas GKOS's P/E ratio is -184.34. In terms of profitability, HJLI's ROE is -0.62%, compared to GKOS's ROE of -0.27%. Regarding short-term risk, HJLI is more volatile compared to GKOS. This indicates higher risk in terms of short-term price fluctuations for HJLI.Check GKOS's competition here

Hancock Jaffe Laboratories (NASDAQ: HJLI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HJLI stands at 98.3M. In comparison, PODD has a market cap of 9.2B. Regarding current trading prices, HJLI is priced at $10.38 on the NASDAQ, while PODD trades at $132.84.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HJLI currently has a P/E ratio of N/A, whereas PODD's P/E ratio is 22.63. In terms of profitability, HJLI's ROE is -0.62%, compared to PODD's ROE of +0.27%. Regarding short-term risk, HJLI is more volatile compared to PODD. This indicates higher risk in terms of short-term price fluctuations for HJLI.Check PODD's competition here

Hancock Jaffe Laboratories (NASDAQ: HJLI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HJLI stands at 98.3M. In comparison, HAE has a market cap of 4.8B. Regarding current trading prices, HJLI is priced at $10.38 on the NASDAQ, while HAE trades at $105.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HJLI currently has a P/E ratio of N/A, whereas HAE's P/E ratio is 21.13. In terms of profitability, HJLI's ROE is -0.62%, compared to HAE's ROE of +0.11%. Regarding short-term risk, HJLI is more volatile compared to HAE. This indicates higher risk in terms of short-term price fluctuations for HJLI.Check HAE's competition here

Hancock Jaffe Laboratories (NASDAQ: HJLI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HJLI stands at 98.3M. In comparison, NARI has a market cap of 4.7B. Regarding current trading prices, HJLI is priced at $10.38 on the NASDAQ, while NARI trades at $79.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HJLI currently has a P/E ratio of N/A, whereas NARI's P/E ratio is -59.24. In terms of profitability, HJLI's ROE is -0.62%, compared to NARI's ROE of -0.00%. Regarding short-term risk, HJLI is more volatile compared to NARI. This indicates higher risk in terms of short-term price fluctuations for HJLI.Check NARI's competition here

Hancock Jaffe Laboratories (NASDAQ: HJLI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HJLI stands at 98.3M. In comparison, ITGR has a market cap of 4.3B. Regarding current trading prices, HJLI is priced at $10.38 on the NASDAQ, while ITGR trades at $126.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HJLI currently has a P/E ratio of N/A, whereas ITGR's P/E ratio is 19.90. In terms of profitability, HJLI's ROE is -0.62%, compared to ITGR's ROE of +0.07%. Regarding short-term risk, HJLI is more volatile compared to ITGR. This indicates higher risk in terms of short-term price fluctuations for HJLI.Check ITGR's competition here

Hancock Jaffe Laboratories (NASDAQ: HJLI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HJLI stands at 98.3M. In comparison, LIVN has a market cap of 4.2B. Regarding current trading prices, HJLI is priced at $10.38 on the NASDAQ, while LIVN trades at $76.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HJLI currently has a P/E ratio of N/A, whereas LIVN's P/E ratio is 18.29. In terms of profitability, HJLI's ROE is -0.62%, compared to LIVN's ROE of +0.15%. Regarding short-term risk, HJLI is more volatile compared to LIVN. This indicates higher risk in terms of short-term price fluctuations for HJLI.Check LIVN's competition here

Hancock Jaffe Laboratories (NASDAQ: HJLI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HJLI stands at 98.3M. In comparison, IRTC has a market cap of 3.8B. Regarding current trading prices, HJLI is priced at $10.38 on the NASDAQ, while IRTC trades at $114.22.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HJLI currently has a P/E ratio of N/A, whereas IRTC's P/E ratio is -265.63. In terms of profitability, HJLI's ROE is -0.62%, compared to IRTC's ROE of -0.09%. Regarding short-term risk, HJLI is less volatile compared to IRTC. This indicates lower risk in terms of short-term price fluctuations for HJLI.Check IRTC's competition here

Hancock Jaffe Laboratories (NASDAQ: HJLI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HJLI stands at 98.3M. In comparison, AXNX has a market cap of 3.6B. Regarding current trading prices, HJLI is priced at $10.38 on the NASDAQ, while AXNX trades at $70.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HJLI currently has a P/E ratio of N/A, whereas AXNX's P/E ratio is -709.80. In terms of profitability, HJLI's ROE is -0.62%, compared to AXNX's ROE of -0.01%. Regarding short-term risk, HJLI is more volatile compared to AXNX. This indicates higher risk in terms of short-term price fluctuations for HJLI.Check AXNX's competition here

Hancock Jaffe Laboratories (NASDAQ: HJLI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HJLI stands at 98.3M. In comparison, TMDX has a market cap of 2.9B. Regarding current trading prices, HJLI is priced at $10.38 on the NASDAQ, while TMDX trades at $84.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HJLI currently has a P/E ratio of N/A, whereas TMDX's P/E ratio is 42.68. In terms of profitability, HJLI's ROE is -0.62%, compared to TMDX's ROE of +0.33%. Regarding short-term risk, HJLI is more volatile compared to TMDX. This indicates higher risk in terms of short-term price fluctuations for HJLI.Check TMDX's competition here

Hancock Jaffe Laboratories (NASDAQ: HJLI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HJLI stands at 98.3M. In comparison, NEOG has a market cap of 2.8B. Regarding current trading prices, HJLI is priced at $10.38 on the NASDAQ, while NEOG trades at $12.73.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HJLI currently has a P/E ratio of N/A, whereas NEOG's P/E ratio is 45.46. In terms of profitability, HJLI's ROE is -0.62%, compared to NEOG's ROE of -0.00%. Regarding short-term risk, HJLI is less volatile compared to NEOG. This indicates lower risk in terms of short-term price fluctuations for HJLI.Check NEOG's competition here

Hancock Jaffe Laboratories (NASDAQ: HJLI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HJLI stands at 98.3M. In comparison, BFLY has a market cap of 2.4B. Regarding current trading prices, HJLI is priced at $10.38 on the NASDAQ, while BFLY trades at $9.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HJLI currently has a P/E ratio of N/A, whereas BFLY's P/E ratio is -37.90. In terms of profitability, HJLI's ROE is -0.62%, compared to BFLY's ROE of -0.38%. Regarding short-term risk, HJLI is less volatile compared to BFLY. This indicates lower risk in terms of short-term price fluctuations for HJLI.Check BFLY's competition here

Hancock Jaffe Laboratories (NASDAQ: HJLI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HJLI stands at 98.3M. In comparison, UFPT has a market cap of 2.3B. Regarding current trading prices, HJLI is priced at $10.38 on the NASDAQ, while UFPT trades at $296.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HJLI currently has a P/E ratio of N/A, whereas UFPT's P/E ratio is 30.33. In terms of profitability, HJLI's ROE is -0.62%, compared to UFPT's ROE of +0.17%. Regarding short-term risk, HJLI is more volatile compared to UFPT. This indicates higher risk in terms of short-term price fluctuations for HJLI.Check UFPT's competition here

Hancock Jaffe Laboratories (NASDAQ: HJLI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HJLI stands at 98.3M. In comparison, AXGN has a market cap of 2.3B. Regarding current trading prices, HJLI is priced at $10.38 on the NASDAQ, while AXGN trades at $42.44.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HJLI currently has a P/E ratio of N/A, whereas AXGN's P/E ratio is 111.68. In terms of profitability, HJLI's ROE is -0.62%, compared to AXGN's ROE of -0.18%. Regarding short-term risk, HJLI is less volatile compared to AXGN. This indicates lower risk in terms of short-term price fluctuations for HJLI.Check AXGN's competition here

Hancock Jaffe Laboratories (NASDAQ: HJLI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HJLI stands at 98.3M. In comparison, INSP has a market cap of 2.1B. Regarding current trading prices, HJLI is priced at $10.38 on the NASDAQ, while INSP trades at $73.18.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HJLI currently has a P/E ratio of N/A, whereas INSP's P/E ratio is 32.26. In terms of profitability, HJLI's ROE is -0.62%, compared to INSP's ROE of +0.18%. Regarding short-term risk, HJLI is less volatile compared to INSP. This indicates lower risk in terms of short-term price fluctuations for HJLI.Check INSP's competition here

Hancock Jaffe Laboratories (NASDAQ: HJLI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HJLI stands at 98.3M. In comparison, NUVA has a market cap of 2.1B. Regarding current trading prices, HJLI is priced at $10.38 on the NASDAQ, while NUVA trades at $39.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HJLI currently has a P/E ratio of N/A, whereas NUVA's P/E ratio is 75.00. In terms of profitability, HJLI's ROE is -0.62%, compared to NUVA's ROE of +0.05%. Regarding short-term risk, HJLI is more volatile compared to NUVA. This indicates higher risk in terms of short-term price fluctuations for HJLI.Check NUVA's competition here

Hancock Jaffe Laboratories (NASDAQ: HJLI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HJLI stands at 98.3M. In comparison, ESTA has a market cap of 1.9B. Regarding current trading prices, HJLI is priced at $10.38 on the NASDAQ, while ESTA trades at $63.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HJLI currently has a P/E ratio of N/A, whereas ESTA's P/E ratio is -50.56. In terms of profitability, HJLI's ROE is -0.62%, compared to ESTA's ROE of -2.04%. Regarding short-term risk, HJLI is less volatile compared to ESTA. This indicates lower risk in terms of short-term price fluctuations for HJLI.Check ESTA's competition here

Hancock Jaffe Laboratories (NASDAQ: HJLI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HJLI stands at 98.3M. In comparison, NVCR has a market cap of 1.9B. Regarding current trading prices, HJLI is priced at $10.38 on the NASDAQ, while NVCR trades at $15.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HJLI currently has a P/E ratio of N/A, whereas NVCR's P/E ratio is -12.30. In terms of profitability, HJLI's ROE is -0.62%, compared to NVCR's ROE of -0.44%. Regarding short-term risk, HJLI is more volatile compared to NVCR. This indicates higher risk in terms of short-term price fluctuations for HJLI.Check NVCR's competition here

Hancock Jaffe Laboratories (NASDAQ: HJLI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HJLI stands at 98.3M. In comparison, ATEC has a market cap of 1.6B. Regarding current trading prices, HJLI is priced at $10.38 on the NASDAQ, while ATEC trades at $10.37.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HJLI currently has a P/E ratio of N/A, whereas ATEC's P/E ratio is -172.83. In terms of profitability, HJLI's ROE is -0.62%, compared to ATEC's ROE of -8.19%. Regarding short-term risk, HJLI is more volatile compared to ATEC. This indicates higher risk in terms of short-term price fluctuations for HJLI.Check ATEC's competition here

Hancock Jaffe Laboratories (NASDAQ: HJLI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HJLI stands at 98.3M. In comparison, CNMD has a market cap of 1.4B. Regarding current trading prices, HJLI is priced at $10.38 on the NASDAQ, while CNMD trades at $46.69.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HJLI currently has a P/E ratio of N/A, whereas CNMD's P/E ratio is 10.26. In terms of profitability, HJLI's ROE is -0.62%, compared to CNMD's ROE of +0.06%. Regarding short-term risk, HJLI is more volatile compared to CNMD. This indicates higher risk in terms of short-term price fluctuations for HJLI.Check CNMD's competition here

Hancock Jaffe Laboratories (NASDAQ: HJLI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HJLI stands at 98.3M. In comparison, HSKA has a market cap of 1.3B. Regarding current trading prices, HJLI is priced at $10.38 on the NASDAQ, while HSKA trades at $119.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HJLI currently has a P/E ratio of N/A, whereas HSKA's P/E ratio is -62.49. In terms of profitability, HJLI's ROE is -0.62%, compared to HSKA's ROE of -0.04%. Regarding short-term risk, HJLI is more volatile compared to HSKA. This indicates higher risk in terms of short-term price fluctuations for HJLI.Check HSKA's competition here

Hancock Jaffe Laboratories (NASDAQ: HJLI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HJLI stands at 98.3M. In comparison, IART has a market cap of 1.3B. Regarding current trading prices, HJLI is priced at $10.38 on the NASDAQ, while IART trades at $16.64.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HJLI currently has a P/E ratio of N/A, whereas IART's P/E ratio is 7.05. In terms of profitability, HJLI's ROE is -0.62%, compared to IART's ROE of -0.01%. Regarding short-term risk, HJLI is less volatile compared to IART. This indicates lower risk in terms of short-term price fluctuations for HJLI.Check IART's competition here

Hancock Jaffe Laboratories (NASDAQ: HJLI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HJLI stands at 98.3M. In comparison, AVNS has a market cap of 1.2B. Regarding current trading prices, HJLI is priced at $10.38 on the NASDAQ, while AVNS trades at $24.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HJLI currently has a P/E ratio of N/A, whereas AVNS's P/E ratio is 27.77. In terms of profitability, HJLI's ROE is -0.62%, compared to AVNS's ROE of -0.09%. Regarding short-term risk, HJLI is more volatile compared to AVNS. This indicates higher risk in terms of short-term price fluctuations for HJLI.Check AVNS's competition here

Hancock Jaffe Laboratories (NASDAQ: HJLI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HJLI stands at 98.3M. In comparison, TNDM has a market cap of 1.1B. Regarding current trading prices, HJLI is priced at $10.38 on the NASDAQ, while TNDM trades at $16.57.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HJLI currently has a P/E ratio of N/A, whereas TNDM's P/E ratio is -17.82. In terms of profitability, HJLI's ROE is -0.62%, compared to TNDM's ROE of -0.46%. Regarding short-term risk, HJLI is less volatile compared to TNDM. This indicates lower risk in terms of short-term price fluctuations for HJLI.Check TNDM's competition here

Hancock Jaffe Laboratories (NASDAQ: HJLI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HJLI stands at 98.3M. In comparison, SILK has a market cap of 1.1B. Regarding current trading prices, HJLI is priced at $10.38 on the NASDAQ, while SILK trades at $27.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HJLI currently has a P/E ratio of N/A, whereas SILK's P/E ratio is -18.96. In terms of profitability, HJLI's ROE is -0.62%, compared to SILK's ROE of -0.35%. Regarding short-term risk, HJLI is more volatile compared to SILK. This indicates higher risk in terms of short-term price fluctuations for HJLI.Check SILK's competition here

Hancock Jaffe Laboratories (NASDAQ: HJLI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HJLI stands at 98.3M. In comparison, AORT has a market cap of 1.1B. Regarding current trading prices, HJLI is priced at $10.38 on the NASDAQ, while AORT trades at $22.86.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HJLI currently has a P/E ratio of N/A, whereas AORT's P/E ratio is 38.07. In terms of profitability, HJLI's ROE is -0.62%, compared to AORT's ROE of -0.01%. Regarding short-term risk, HJLI is more volatile compared to AORT. This indicates higher risk in terms of short-term price fluctuations for HJLI.Check AORT's competition here

Hancock Jaffe Laboratories (NASDAQ: HJLI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HJLI stands at 98.3M. In comparison, IRMD has a market cap of 1.1B. Regarding current trading prices, HJLI is priced at $10.38 on the NASDAQ, while IRMD trades at $86.46.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HJLI currently has a P/E ratio of N/A, whereas IRMD's P/E ratio is 43.45. In terms of profitability, HJLI's ROE is -0.62%, compared to IRMD's ROE of +0.23%. Regarding short-term risk, HJLI is more volatile compared to IRMD. This indicates higher risk in terms of short-term price fluctuations for HJLI.Check IRMD's competition here

Hancock Jaffe Laboratories (NASDAQ: HJLI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HJLI stands at 98.3M. In comparison, FNA has a market cap of 1.1B. Regarding current trading prices, HJLI is priced at $10.38 on the NASDAQ, while FNA trades at $13.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HJLI currently has a P/E ratio of N/A, whereas FNA's P/E ratio is -19.83. In terms of profitability, HJLI's ROE is -0.62%, compared to FNA's ROE of -0.35%. Regarding short-term risk, HJLI is more volatile compared to FNA. This indicates higher risk in terms of short-term price fluctuations for HJLI.Check FNA's competition here

Hancock Jaffe Laboratories (NASDAQ: HJLI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HJLI stands at 98.3M. In comparison, ENOV has a market cap of 1.1B. Regarding current trading prices, HJLI is priced at $10.38 on the NASDAQ, while ENOV trades at $18.46.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HJLI currently has a P/E ratio of N/A, whereas ENOV's P/E ratio is 5.29. In terms of profitability, HJLI's ROE is -0.62%, compared to ENOV's ROE of -0.68%. Regarding short-term risk, HJLI is more volatile compared to ENOV. This indicates higher risk in terms of short-term price fluctuations for HJLI.Check ENOV's competition here

Hancock Jaffe Laboratories (NASDAQ: HJLI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HJLI stands at 98.3M. In comparison, PRCT has a market cap of 1B. Regarding current trading prices, HJLI is priced at $10.38 on the NASDAQ, while PRCT trades at $18.22.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HJLI currently has a P/E ratio of N/A, whereas PRCT's P/E ratio is -9.39. In terms of profitability, HJLI's ROE is -0.62%, compared to PRCT's ROE of -0.31%. Regarding short-term risk, HJLI is less volatile compared to PRCT. This indicates lower risk in terms of short-term price fluctuations for HJLI.Check PRCT's competition here

Hancock Jaffe Laboratories (NASDAQ: HJLI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HJLI stands at 98.3M. In comparison, LMRI has a market cap of 985.8M. Regarding current trading prices, HJLI is priced at $10.38 on the NASDAQ, while LMRI trades at $10.26.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HJLI currently has a P/E ratio of N/A, whereas LMRI's P/E ratio is -19.96. In terms of profitability, HJLI's ROE is -0.62%, compared to LMRI's ROE of -0.06%. Regarding short-term risk, HJLI is more volatile compared to LMRI. This indicates higher risk in terms of short-term price fluctuations for HJLI.Check LMRI's competition here

Hancock Jaffe Laboratories (NASDAQ: HJLI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HJLI stands at 98.3M. In comparison, BVS has a market cap of 948.5M. Regarding current trading prices, HJLI is priced at $10.38 on the NASDAQ, while BVS trades at $14.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HJLI currently has a P/E ratio of N/A, whereas BVS's P/E ratio is 18.42. In terms of profitability, HJLI's ROE is -0.62%, compared to BVS's ROE of +0.28%. Regarding short-term risk, HJLI is more volatile compared to BVS. This indicates higher risk in terms of short-term price fluctuations for HJLI.Check BVS's competition here

Hancock Jaffe Laboratories (NASDAQ: HJLI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HJLI stands at 98.3M. In comparison, CBLL has a market cap of 943.3M. Regarding current trading prices, HJLI is priced at $10.38 on the NASDAQ, while CBLL trades at $24.86.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HJLI currently has a P/E ratio of N/A, whereas CBLL's P/E ratio is -14.12. In terms of profitability, HJLI's ROE is -0.62%, compared to CBLL's ROE of -0.45%. Regarding short-term risk, HJLI is more volatile compared to CBLL. This indicates higher risk in terms of short-term price fluctuations for HJLI.Check CBLL's competition here

Hancock Jaffe Laboratories (NASDAQ: HJLI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HJLI stands at 98.3M. In comparison, BBNX has a market cap of 873.2M. Regarding current trading prices, HJLI is priced at $10.38 on the NASDAQ, while BBNX trades at $19.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HJLI currently has a P/E ratio of N/A, whereas BBNX's P/E ratio is -11.76. In terms of profitability, HJLI's ROE is -0.62%, compared to BBNX's ROE of -0.26%. Regarding short-term risk, HJLI is less volatile compared to BBNX. This indicates lower risk in terms of short-term price fluctuations for HJLI.Check BBNX's competition here

Hancock Jaffe Laboratories (NASDAQ: HJLI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HJLI stands at 98.3M. In comparison, SIBN has a market cap of 849.3M. Regarding current trading prices, HJLI is priced at $10.38 on the NASDAQ, while SIBN trades at $19.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HJLI currently has a P/E ratio of N/A, whereas SIBN's P/E ratio is -56.32. In terms of profitability, HJLI's ROE is -0.62%, compared to SIBN's ROE of -0.08%. Regarding short-term risk, HJLI is less volatile compared to SIBN. This indicates lower risk in terms of short-term price fluctuations for HJLI.Check SIBN's competition here

Hancock Jaffe Laboratories (NASDAQ: HJLI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HJLI stands at 98.3M. In comparison, CSII has a market cap of 844M. Regarding current trading prices, HJLI is priced at $10.38 on the NASDAQ, while CSII trades at $20.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HJLI currently has a P/E ratio of N/A, whereas CSII's P/E ratio is -20.83. In terms of profitability, HJLI's ROE is -0.62%, compared to CSII's ROE of -0.14%. Regarding short-term risk, HJLI is more volatile compared to CSII. This indicates higher risk in terms of short-term price fluctuations for HJLI.Check CSII's competition here

Hancock Jaffe Laboratories (NASDAQ: HJLI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HJLI stands at 98.3M. In comparison, INMD has a market cap of 817.4M. Regarding current trading prices, HJLI is priced at $10.38 on the NASDAQ, while INMD trades at $14.22.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HJLI currently has a P/E ratio of N/A, whereas INMD's P/E ratio is 9.88. In terms of profitability, HJLI's ROE is -0.62%, compared to INMD's ROE of +0.12%. Regarding short-term risk, HJLI is more volatile compared to INMD. This indicates higher risk in terms of short-term price fluctuations for HJLI.Check INMD's competition here

Hancock Jaffe Laboratories (NASDAQ: HJLI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HJLI stands at 98.3M. In comparison, VREX has a market cap of 777.6M. Regarding current trading prices, HJLI is priced at $10.38 on the NASDAQ, while VREX trades at $18.47.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HJLI currently has a P/E ratio of N/A, whereas VREX's P/E ratio is 19.44. In terms of profitability, HJLI's ROE is -0.62%, compared to VREX's ROE of +0.05%. Regarding short-term risk, HJLI is more volatile compared to VREX. This indicates higher risk in terms of short-term price fluctuations for HJLI.Check VREX's competition here

Hancock Jaffe Laboratories (NASDAQ: HJLI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HJLI stands at 98.3M. In comparison, AHCO has a market cap of 771.4M. Regarding current trading prices, HJLI is priced at $10.38 on the NASDAQ, while AHCO trades at $5.67.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HJLI currently has a P/E ratio of N/A, whereas AHCO's P/E ratio is 11.57. In terms of profitability, HJLI's ROE is -0.62%, compared to AHCO's ROE of -0.15%. Regarding short-term risk, HJLI is more volatile compared to AHCO. This indicates higher risk in terms of short-term price fluctuations for HJLI.Check AHCO's competition here

Hancock Jaffe Laboratories (NASDAQ: HJLI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HJLI stands at 98.3M. In comparison, CTKB has a market cap of 743.9M. Regarding current trading prices, HJLI is priced at $10.38 on the NASDAQ, while CTKB trades at $5.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HJLI currently has a P/E ratio of N/A, whereas CTKB's P/E ratio is -30.51. In terms of profitability, HJLI's ROE is -0.62%, compared to CTKB's ROE of -0.24%. Regarding short-term risk, HJLI is more volatile compared to CTKB. This indicates higher risk in terms of short-term price fluctuations for HJLI.Check CTKB's competition here

Hancock Jaffe Laboratories (NASDAQ: HJLI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HJLI stands at 98.3M. In comparison, AVR has a market cap of 738M. Regarding current trading prices, HJLI is priced at $10.38 on the NASDAQ, while AVR trades at $7.59.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HJLI currently has a P/E ratio of N/A, whereas AVR's P/E ratio is -3.91. In terms of profitability, HJLI's ROE is -0.62%, compared to AVR's ROE of -0.78%. Regarding short-term risk, HJLI is more volatile compared to AVR. This indicates higher risk in terms of short-term price fluctuations for HJLI.Check AVR's competition here

Hancock Jaffe Laboratories (NASDAQ: HJLI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HJLI stands at 98.3M. In comparison, SRDX has a market cap of 614.5M. Regarding current trading prices, HJLI is priced at $10.38 on the NASDAQ, while SRDX trades at $42.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HJLI currently has a P/E ratio of N/A, whereas SRDX's P/E ratio is -34.66. In terms of profitability, HJLI's ROE is -0.62%, compared to SRDX's ROE of -0.10%. Regarding short-term risk, HJLI is more volatile compared to SRDX. This indicates higher risk in terms of short-term price fluctuations for HJLI.Check SRDX's competition here

Hancock Jaffe Laboratories (NASDAQ: HJLI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HJLI stands at 98.3M. In comparison, KIDS has a market cap of 584.6M. Regarding current trading prices, HJLI is priced at $10.38 on the NASDAQ, while KIDS trades at $22.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HJLI currently has a P/E ratio of N/A, whereas KIDS's P/E ratio is -19.29. In terms of profitability, HJLI's ROE is -0.62%, compared to KIDS's ROE of -0.12%. Regarding short-term risk, HJLI is more volatile compared to KIDS. This indicates higher risk in terms of short-term price fluctuations for HJLI.Check KIDS's competition here

Hancock Jaffe Laboratories (NASDAQ: HJLI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HJLI stands at 98.3M. In comparison, APEN has a market cap of 579.7M. Regarding current trading prices, HJLI is priced at $10.38 on the NASDAQ, while APEN trades at $10.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HJLI currently has a P/E ratio of N/A, whereas APEN's P/E ratio is -9.43. In terms of profitability, HJLI's ROE is -0.62%, compared to APEN's ROE of -0.85%. Regarding short-term risk, HJLI is more volatile compared to APEN. This indicates higher risk in terms of short-term price fluctuations for HJLI.Check APEN's competition here

Hancock Jaffe Laboratories (NASDAQ: HJLI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HJLI stands at 98.3M. In comparison, SSII has a market cap of 578.4M. Regarding current trading prices, HJLI is priced at $10.38 on the NASDAQ, while SSII trades at $2.89.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HJLI currently has a P/E ratio of N/A, whereas SSII's P/E ratio is -48.17. In terms of profitability, HJLI's ROE is -0.62%, compared to SSII's ROE of -0.27%. Regarding short-term risk, HJLI is less volatile compared to SSII. This indicates lower risk in terms of short-term price fluctuations for HJLI.Check SSII's competition here

Hancock Jaffe Laboratories (NASDAQ: HJLI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HJLI stands at 98.3M. In comparison, PACB has a market cap of 568.4M. Regarding current trading prices, HJLI is priced at $10.38 on the NASDAQ, while PACB trades at $1.83.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HJLI currently has a P/E ratio of N/A, whereas PACB's P/E ratio is -4.46. In terms of profitability, HJLI's ROE is -0.62%, compared to PACB's ROE of -49.62%. Regarding short-term risk, HJLI is less volatile compared to PACB. This indicates lower risk in terms of short-term price fluctuations for HJLI.Check PACB's competition here

Hancock Jaffe Laboratories (NASDAQ: HJLI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HJLI stands at 98.3M. In comparison, DCTH has a market cap of 547.2M. Regarding current trading prices, HJLI is priced at $10.38 on the NASDAQ, while DCTH trades at $15.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HJLI currently has a P/E ratio of N/A, whereas DCTH's P/E ratio is 1585.00. In terms of profitability, HJLI's ROE is -0.62%, compared to DCTH's ROE of +0.00%. Regarding short-term risk, HJLI is more volatile compared to DCTH. This indicates higher risk in terms of short-term price fluctuations for HJLI.Check DCTH's competition here

Hancock Jaffe Laboratories (NASDAQ: HJLI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HJLI stands at 98.3M. In comparison, ZIMV has a market cap of 535.6M. Regarding current trading prices, HJLI is priced at $10.38 on the NASDAQ, while ZIMV trades at $18.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HJLI currently has a P/E ratio of N/A, whereas ZIMV's P/E ratio is -27.52. In terms of profitability, HJLI's ROE is -0.62%, compared to ZIMV's ROE of -0.01%. Regarding short-term risk, HJLI is more volatile compared to ZIMV. This indicates higher risk in terms of short-term price fluctuations for HJLI.Check ZIMV's competition here

Hancock Jaffe Laboratories (NASDAQ: HJLI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HJLI stands at 98.3M. In comparison, SGHT has a market cap of 508.7M. Regarding current trading prices, HJLI is priced at $10.38 on the NASDAQ, while SGHT trades at $9.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HJLI currently has a P/E ratio of N/A, whereas SGHT's P/E ratio is -16.70. In terms of profitability, HJLI's ROE is -0.62%, compared to SGHT's ROE of -0.51%. Regarding short-term risk, HJLI is more volatile compared to SGHT. This indicates higher risk in terms of short-term price fluctuations for HJLI.Check SGHT's competition here

Hancock Jaffe Laboratories (NASDAQ: HJLI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HJLI stands at 98.3M. In comparison, TCMD has a market cap of 508.2M. Regarding current trading prices, HJLI is priced at $10.38 on the NASDAQ, while TCMD trades at $22.53.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HJLI currently has a P/E ratio of N/A, whereas TCMD's P/E ratio is 20.86. In terms of profitability, HJLI's ROE is -0.62%, compared to TCMD's ROE of +0.11%. Regarding short-term risk, HJLI is more volatile compared to TCMD. This indicates higher risk in terms of short-term price fluctuations for HJLI.Check TCMD's competition here

Hancock Jaffe Laboratories (NASDAQ: HJLI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HJLI stands at 98.3M. In comparison, CERS has a market cap of 497.8M. Regarding current trading prices, HJLI is priced at $10.38 on the NASDAQ, while CERS trades at $2.47.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HJLI currently has a P/E ratio of N/A, whereas CERS's P/E ratio is -82.06. In terms of profitability, HJLI's ROE is -0.62%, compared to CERS's ROE of -0.10%. Regarding short-term risk, HJLI is more volatile compared to CERS. This indicates higher risk in terms of short-term price fluctuations for HJLI.Check CERS's competition here

Hancock Jaffe Laboratories (NASDAQ: HJLI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HJLI stands at 98.3M. In comparison, NPCE has a market cap of 475.3M. Regarding current trading prices, HJLI is priced at $10.38 on the NASDAQ, while NPCE trades at $13.94.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HJLI currently has a P/E ratio of N/A, whereas NPCE's P/E ratio is -24.46. In terms of profitability, HJLI's ROE is -0.62%, compared to NPCE's ROE of -1.20%. Regarding short-term risk, HJLI is less volatile compared to NPCE. This indicates lower risk in terms of short-term price fluctuations for HJLI.Check NPCE's competition here

Hancock Jaffe Laboratories (NASDAQ: HJLI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HJLI stands at 98.3M. In comparison, SENS has a market cap of 420M. Regarding current trading prices, HJLI is priced at $10.38 on the NASDAQ, while SENS trades at $10.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HJLI currently has a P/E ratio of N/A, whereas SENS's P/E ratio is -4.51. In terms of profitability, HJLI's ROE is -0.62%, compared to SENS's ROE of -1.66%. Regarding short-term risk, HJLI is more volatile compared to SENS. This indicates higher risk in terms of short-term price fluctuations for HJLI.Check SENS's competition here

Hancock Jaffe Laboratories (NASDAQ: HJLI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HJLI stands at 98.3M. In comparison, OFIX has a market cap of 394.1M. Regarding current trading prices, HJLI is priced at $10.38 on the NASDAQ, while OFIX trades at $9.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HJLI currently has a P/E ratio of N/A, whereas OFIX's P/E ratio is -6.35. In terms of profitability, HJLI's ROE is -0.62%, compared to OFIX's ROE of -0.14%. Regarding short-term risk, HJLI is more volatile compared to OFIX. This indicates higher risk in terms of short-term price fluctuations for HJLI.Check OFIX's competition here

Hancock Jaffe Laboratories (NASDAQ: HJLI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HJLI stands at 98.3M. In comparison, CLPT has a market cap of 353M. Regarding current trading prices, HJLI is priced at $10.38 on the NASDAQ, while CLPT trades at $11.77.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HJLI currently has a P/E ratio of N/A, whereas CLPT's P/E ratio is -9.97. In terms of profitability, HJLI's ROE is -0.62%, compared to CLPT's ROE of -1.88%. Regarding short-term risk, HJLI is less volatile compared to CLPT. This indicates lower risk in terms of short-term price fluctuations for HJLI.Check CLPT's competition here

Hancock Jaffe Laboratories (NASDAQ: HJLI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HJLI stands at 98.3M. In comparison, CV has a market cap of 334.3M. Regarding current trading prices, HJLI is priced at $10.38 on the NASDAQ, while CV trades at $6.69.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HJLI currently has a P/E ratio of N/A, whereas CV's P/E ratio is -10.62. In terms of profitability, HJLI's ROE is -0.62%, compared to CV's ROE of -1.78%. Regarding short-term risk, HJLI is less volatile compared to CV. This indicates lower risk in terms of short-term price fluctuations for HJLI.Check CV's competition here

Hancock Jaffe Laboratories (NASDAQ: HJLI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HJLI stands at 98.3M. In comparison, SMLR has a market cap of 310.7M. Regarding current trading prices, HJLI is priced at $10.38 on the NASDAQ, while SMLR trades at $20.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HJLI currently has a P/E ratio of N/A, whereas SMLR's P/E ratio is 3.92. In terms of profitability, HJLI's ROE is -0.62%, compared to SMLR's ROE of +0.06%. Regarding short-term risk, HJLI is more volatile compared to SMLR. This indicates higher risk in terms of short-term price fluctuations for HJLI.Check SMLR's competition here

Hancock Jaffe Laboratories (NASDAQ: HJLI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HJLI stands at 98.3M. In comparison, TMCI has a market cap of 299.7M. Regarding current trading prices, HJLI is priced at $10.38 on the NASDAQ, while TMCI trades at $4.62.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HJLI currently has a P/E ratio of N/A, whereas TMCI's P/E ratio is -4.91. In terms of profitability, HJLI's ROE is -0.62%, compared to TMCI's ROE of -0.74%. Regarding short-term risk, HJLI is less volatile compared to TMCI. This indicates lower risk in terms of short-term price fluctuations for HJLI.Check TMCI's competition here

Hancock Jaffe Laboratories (NASDAQ: HJLI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HJLI stands at 98.3M. In comparison, CATX has a market cap of 298.8M. Regarding current trading prices, HJLI is priced at $10.38 on the NASDAQ, while CATX trades at $2.62.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HJLI currently has a P/E ratio of N/A, whereas CATX's P/E ratio is -1.97. In terms of profitability, HJLI's ROE is -0.62%, compared to CATX's ROE of -0.42%. Regarding short-term risk, HJLI is less volatile compared to CATX. This indicates lower risk in terms of short-term price fluctuations for HJLI.Check CATX's competition here

Hancock Jaffe Laboratories (NASDAQ: HJLI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HJLI stands at 98.3M. In comparison, RCEL has a market cap of 297.1M. Regarding current trading prices, HJLI is priced at $10.38 on the NASDAQ, while RCEL trades at $11.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HJLI currently has a P/E ratio of N/A, whereas RCEL's P/E ratio is -8.31. In terms of profitability, HJLI's ROE is -0.62%, compared to RCEL's ROE of +2.32%. Regarding short-term risk, HJLI is more volatile compared to RCEL. This indicates higher risk in terms of short-term price fluctuations for HJLI.Check RCEL's competition here

Hancock Jaffe Laboratories (NASDAQ: HJLI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HJLI stands at 98.3M. In comparison, INFU has a market cap of 263M. Regarding current trading prices, HJLI is priced at $10.38 on the NASDAQ, while INFU trades at $13.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HJLI currently has a P/E ratio of N/A, whereas INFU's P/E ratio is 31.78. In terms of profitability, HJLI's ROE is -0.62%, compared to INFU's ROE of +0.15%. Regarding short-term risk, HJLI is more volatile compared to INFU. This indicates higher risk in terms of short-term price fluctuations for HJLI.Check INFU's competition here

Hancock Jaffe Laboratories (NASDAQ: HJLI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HJLI stands at 98.3M. In comparison, TLSI has a market cap of 261.7M. Regarding current trading prices, HJLI is priced at $10.38 on the NASDAQ, while TLSI trades at $4.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HJLI currently has a P/E ratio of N/A, whereas TLSI's P/E ratio is -2.53. In terms of profitability, HJLI's ROE is -0.62%, compared to TLSI's ROE of +2.74%. Regarding short-term risk, HJLI is less volatile compared to TLSI. This indicates lower risk in terms of short-term price fluctuations for HJLI.Check TLSI's competition here

Hancock Jaffe Laboratories (NASDAQ: HJLI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HJLI stands at 98.3M. In comparison, MGRM has a market cap of 243.8M. Regarding current trading prices, HJLI is priced at $10.38 on the NASDAQ, while MGRM trades at $6.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HJLI currently has a P/E ratio of N/A, whereas MGRM's P/E ratio is -12.00. In terms of profitability, HJLI's ROE is -0.62%, compared to MGRM's ROE of -0.85%. Regarding short-term risk, HJLI is more volatile compared to MGRM. This indicates higher risk in terms of short-term price fluctuations for HJLI.Check MGRM's competition here

Hancock Jaffe Laboratories (NASDAQ: HJLI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HJLI stands at 98.3M. In comparison, ELMD has a market cap of 232.9M. Regarding current trading prices, HJLI is priced at $10.38 on the NASDAQ, while ELMD trades at $28.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HJLI currently has a P/E ratio of N/A, whereas ELMD's P/E ratio is 21.47. In terms of profitability, HJLI's ROE is -0.62%, compared to ELMD's ROE of +0.23%. Regarding short-term risk, HJLI is more volatile compared to ELMD. This indicates higher risk in terms of short-term price fluctuations for HJLI.Check ELMD's competition here

Hancock Jaffe Laboratories (NASDAQ: HJLI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HJLI stands at 98.3M. In comparison, NVRO has a market cap of 224.1M. Regarding current trading prices, HJLI is priced at $10.38 on the NASDAQ, while NVRO trades at $5.84.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HJLI currently has a P/E ratio of N/A, whereas NVRO's P/E ratio is -1.91. In terms of profitability, HJLI's ROE is -0.62%, compared to NVRO's ROE of -0.43%. Regarding short-term risk, HJLI is more volatile compared to NVRO. This indicates higher risk in terms of short-term price fluctuations for HJLI.Check NVRO's competition here

Hancock Jaffe Laboratories (NASDAQ: HJLI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HJLI stands at 98.3M. In comparison, PROF has a market cap of 207.9M. Regarding current trading prices, HJLI is priced at $10.38 on the NASDAQ, while PROF trades at $5.72.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HJLI currently has a P/E ratio of N/A, whereas PROF's P/E ratio is -5.84. In terms of profitability, HJLI's ROE is -0.62%, compared to PROF's ROE of -0.56%. Regarding short-term risk, HJLI is more volatile compared to PROF. This indicates higher risk in terms of short-term price fluctuations for HJLI.Check PROF's competition here

Hancock Jaffe Laboratories (NASDAQ: HJLI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HJLI stands at 98.3M. In comparison, RXST has a market cap of 197.5M. Regarding current trading prices, HJLI is priced at $10.38 on the NASDAQ, while RXST trades at $4.77.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HJLI currently has a P/E ratio of N/A, whereas RXST's P/E ratio is -4.22. In terms of profitability, HJLI's ROE is -0.62%, compared to RXST's ROE of -0.17%. Regarding short-term risk, HJLI is more volatile compared to RXST. This indicates higher risk in terms of short-term price fluctuations for HJLI.Check RXST's competition here

Hancock Jaffe Laboratories (NASDAQ: HJLI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HJLI stands at 98.3M. In comparison, BSGM has a market cap of 191.1M. Regarding current trading prices, HJLI is priced at $10.38 on the NASDAQ, while BSGM trades at $6.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HJLI currently has a P/E ratio of N/A, whereas BSGM's P/E ratio is -5.81. In terms of profitability, HJLI's ROE is -0.62%, compared to BSGM's ROE of +15.26%. Regarding short-term risk, HJLI is less volatile compared to BSGM. This indicates lower risk in terms of short-term price fluctuations for HJLI.Check BSGM's competition here

Hancock Jaffe Laboratories (NASDAQ: HJLI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HJLI stands at 98.3M. In comparison, QSI has a market cap of 189.5M. Regarding current trading prices, HJLI is priced at $10.38 on the NASDAQ, while QSI trades at $0.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HJLI currently has a P/E ratio of N/A, whereas QSI's P/E ratio is -2.08. In terms of profitability, HJLI's ROE is -0.62%, compared to QSI's ROE of -0.47%. Regarding short-term risk, HJLI is less volatile compared to QSI. This indicates lower risk in terms of short-term price fluctuations for HJLI.Check QSI's competition here

Hancock Jaffe Laboratories (NASDAQ: HJLI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HJLI stands at 98.3M. In comparison, MDGS has a market cap of 178.9M. Regarding current trading prices, HJLI is priced at $10.38 on the NASDAQ, while MDGS trades at $2.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HJLI currently has a P/E ratio of N/A, whereas MDGS's P/E ratio is -0.27. In terms of profitability, HJLI's ROE is -0.62%, compared to MDGS's ROE of -0.51%. Regarding short-term risk, HJLI is less volatile compared to MDGS. This indicates lower risk in terms of short-term price fluctuations for HJLI.Check MDGS's competition here

Hancock Jaffe Laboratories (NASDAQ: HJLI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HJLI stands at 98.3M. In comparison, QTRX has a market cap of 172.9M. Regarding current trading prices, HJLI is priced at $10.38 on the NASDAQ, while QTRX trades at $3.67.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HJLI currently has a P/E ratio of N/A, whereas QTRX's P/E ratio is -1.44. In terms of profitability, HJLI's ROE is -0.62%, compared to QTRX's ROE of -0.44%. Regarding short-term risk, HJLI is less volatile compared to QTRX. This indicates lower risk in terms of short-term price fluctuations for HJLI.Check QTRX's competition here

Hancock Jaffe Laboratories (NASDAQ: HJLI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HJLI stands at 98.3M. In comparison, FOCL has a market cap of 170.2M. Regarding current trading prices, HJLI is priced at $10.38 on the NASDAQ, while FOCL trades at $4.54.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HJLI currently has a P/E ratio of N/A, whereas FOCL's P/E ratio is -4.39. In terms of profitability, HJLI's ROE is -0.62%, compared to FOCL's ROE of -2.90%. Regarding short-term risk, HJLI is less volatile compared to FOCL. This indicates lower risk in terms of short-term price fluctuations for HJLI.Check FOCL's competition here

Hancock Jaffe Laboratories (NASDAQ: HJLI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HJLI stands at 98.3M. In comparison, STIM has a market cap of 164.2M. Regarding current trading prices, HJLI is priced at $10.38 on the NASDAQ, while STIM trades at $2.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HJLI currently has a P/E ratio of N/A, whereas STIM's P/E ratio is -5.36. In terms of profitability, HJLI's ROE is -0.62%, compared to STIM's ROE of -1.51%. Regarding short-term risk, HJLI is less volatile compared to STIM. This indicates lower risk in terms of short-term price fluctuations for HJLI.Check STIM's competition here

Hancock Jaffe Laboratories (NASDAQ: HJLI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HJLI stands at 98.3M. In comparison, QIPT has a market cap of 162.3M. Regarding current trading prices, HJLI is priced at $10.38 on the NASDAQ, while QIPT trades at $3.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HJLI currently has a P/E ratio of N/A, whereas QIPT's P/E ratio is -15.87. In terms of profitability, HJLI's ROE is -0.62%, compared to QIPT's ROE of -0.10%. Regarding short-term risk, HJLI is more volatile compared to QIPT. This indicates higher risk in terms of short-term price fluctuations for HJLI.Check QIPT's competition here

Hancock Jaffe Laboratories (NASDAQ: HJLI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HJLI stands at 98.3M. In comparison, LUCD has a market cap of 154.3M. Regarding current trading prices, HJLI is priced at $10.38 on the NASDAQ, while LUCD trades at $0.81.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HJLI currently has a P/E ratio of N/A, whereas LUCD's P/E ratio is -2.19. In terms of profitability, HJLI's ROE is -0.62%, compared to LUCD's ROE of -4.04%. Regarding short-term risk, HJLI is more volatile compared to LUCD. This indicates higher risk in terms of short-term price fluctuations for HJLI.Check LUCD's competition here

Hancock Jaffe Laboratories (NASDAQ: HJLI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HJLI stands at 98.3M. In comparison, INGN has a market cap of 145.4M. Regarding current trading prices, HJLI is priced at $10.38 on the NASDAQ, while INGN trades at $5.37.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HJLI currently has a P/E ratio of N/A, whereas INGN's P/E ratio is -5.90. In terms of profitability, HJLI's ROE is -0.62%, compared to INGN's ROE of -0.13%. Regarding short-term risk, HJLI is more volatile compared to INGN. This indicates higher risk in terms of short-term price fluctuations for HJLI.Check INGN's competition here

Hancock Jaffe Laboratories (NASDAQ: HJLI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HJLI stands at 98.3M. In comparison, ICAD has a market cap of 106.3M. Regarding current trading prices, HJLI is priced at $10.38 on the NASDAQ, while ICAD trades at $3.87.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HJLI currently has a P/E ratio of N/A, whereas ICAD's P/E ratio is -20.37. In terms of profitability, HJLI's ROE is -0.62%, compared to ICAD's ROE of -0.18%. Regarding short-term risk, HJLI is more volatile compared to ICAD. This indicates higher risk in terms of short-term price fluctuations for HJLI.Check ICAD's competition here

Hancock Jaffe Laboratories (NASDAQ: HJLI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HJLI stands at 98.3M. In comparison, ECOR has a market cap of 98.1M. Regarding current trading prices, HJLI is priced at $10.38 on the NASDAQ, while ECOR trades at $10.88.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HJLI currently has a P/E ratio of N/A, whereas ECOR's P/E ratio is -6.48. In terms of profitability, HJLI's ROE is -0.62%, compared to ECOR's ROE of +5.25%. Regarding short-term risk, HJLI is less volatile compared to ECOR. This indicates lower risk in terms of short-term price fluctuations for HJLI.Check ECOR's competition here

Hancock Jaffe Laboratories (NASDAQ: HJLI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, HJLI stands at 98.3M. In comparison, ASXC has a market cap of 94.9M. Regarding current trading prices, HJLI is priced at $10.38 on the NASDAQ, while ASXC trades at $0.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

HJLI currently has a P/E ratio of N/A, whereas ASXC's P/E ratio is -1.12. In terms of profitability, HJLI's ROE is -0.62%, compared to ASXC's ROE of -1.18%. Regarding short-term risk, HJLI is more volatile compared to ASXC. This indicates higher risk in terms of short-term price fluctuations for HJLI.Check ASXC's competition here